公开(公告)号：US20250057815A1

公开(公告)日：2025-02-20

申请号：US18822597

申请日：2024-09-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Babu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: A61K31/4192 ,  A61K31/27 ,  A61K31/41 ,  A61K31/454 ,  C07C62/10 ,  C07D249/06 ,  C07D401/04 ,  C07D401/14

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11352345B2

公开(公告)日：2022-06-07

申请号：US16954320

申请日：2018-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter Tai Wah Cheng ,  Hao Zhang ,  Jun Li ,  Tianan Fang ,  James R. Corte

IPC: C07D403/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20210379210A1

公开(公告)日：2021-12-09

申请号：US17285194

申请日：2019-10-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  James R. Corte ,  David J. Donnelly ,  Joonyoung Kim ,  Jun Shi ,  Shiwei Tao ,  Tritin Tran

IPC: A61K51/04 ,  C07D401/04

Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists of Formula (I) or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein, which are useful for the quantitative imaging of LPA1 receptors in mammals.

公开(公告)号：US20210244711A1

公开(公告)日：2021-08-12

申请号：US17221859

申请日：2021-04-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： PETER TAI WAH CHENG ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Babu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: A61K31/4192 ,  C07D401/14 ,  C07D249/06 ,  A61K31/27 ,  A61K31/454 ,  C07D401/04

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11053247B2

公开(公告)日：2021-07-06

申请号：US16451873

申请日：2019-06-25

Applicant: Bristol-Myers Squibb Company

Inventor： Andrew K. Dilger ,  James R. Corte ,  Indawati De Lucca ,  Tianan Fang ,  Wu Yang ,  Yufeng Wang ,  Kumar Balashanmuga Pabbisetty ,  William R. Ewing ,  Yeheng Zhu ,  Ruth R. Wexler ,  Donald J. P. Pinto ,  Michael J. Orwat ,  Leon M. Smith, II

IPC: C07D471/18 ,  C07F7/08 ,  C07D519/00 ,  C07D471/08 ,  C07D487/08

Abstract: The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20190144393A1

公开(公告)日：2019-05-16

申请号：US16245745

申请日：2019-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James R. Corte ,  Andrew K. Dilger ,  William R. Ewing ,  Donald J.P. Pinto ,  Wu Yang

IPC: C07D225/06 ,  C07D471/04 ,  C07D245/06 ,  C07D487/08 ,  C07D403/04 ,  A61P7/02 ,  C07D401/04 ,  C07D471/08

Abstract: The present invention provides compounds of Formula (I): P-Ma  (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20180265494A1

公开(公告)日：2018-09-20

申请号：US15982038

申请日：2018-05-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Michael J. Orwat ,  Donald J.P. Pinto ,  Leon M. Smith, II ,  James R. Corte ,  Shefali Srivastava

IPC: C07D401/10 ,  C07D487/04 ,  C07D471/04 ,  C07D401/14 ,  C07D217/26 ,  C07D413/14 ,  C07D401/12

CPC classification number: C07D401/10 ,  C07D217/26 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

公开(公告)号：US20180148461A1

公开(公告)日：2018-05-31

申请号：US15879619

申请日：2018-01-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Donald J.P. Pinto ,  James R. Corte ,  Wu Yang ,  William R. Ewing

IPC: C07D519/00 ,  C07D487/08 ,  C07D498/08 ,  C07D471/08

CPC classification number: C07D519/00 ,  C07D471/06 ,  C07D471/08 ,  C07D487/06 ,  C07D487/08 ,  C07D498/06 ,  C07D498/08

Abstract: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20170158712A1

公开(公告)日：2017-06-08

申请号：US15437605

申请日：2017-02-21

Applicant: Bristol-Myers Squibb Company

Inventor： Donald J. P. Pinto ,  James R. Corte ,  Paul J. Gilligan ,  Tianan Fang ,  Leon M. Smith, II ,  Yufeng Wang ,  Wu Yang ,  William R. Ewing

IPC: C07D519/00 ,  C07D487/08 ,  C07D498/08 ,  C07D471/08

CPC classification number: C07D519/00 ,  C07D471/06 ,  C07D471/08 ,  C07D487/06 ,  C07D487/08 ,  C07D498/06 ,  C07D498/08

Abstract: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20160368923A1

公开(公告)日：2016-12-22

申请号：US15221142

申请日：2016-07-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew K. Dilger ,  James R. Corte ,  lndawati De Lucca ,  Tianan Fang ,  Wu Yang ,  Yufeng Wang ,  Kumar Balashanmuga Pabbisetty ,  William R. Ewing ,  Yeheng Zhu ,  Ruth R. Wexler ,  Donald J.P. Pinto ,  Michael J. Orwat ,  Leon M. Smith II

IPC: C07D471/18 ,  C07D519/00 ,  C07F7/08 ,  C07D487/08 ,  C07D471/08

CPC classification number: C07D471/18 ,  C07D471/08 ,  C07D487/08 ,  C07D519/00 ,  C07F7/0814

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract translation: 或立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。